The Significance of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in the Early Postoperative Recurrence Monitoring and Prognosis Prediction of AFP-Negative Hepatocellular Carcinoma
- PMID: 33604313
- PMCID: PMC7881779
- DOI: 10.2147/JHC.S286213
The Significance of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in the Early Postoperative Recurrence Monitoring and Prognosis Prediction of AFP-Negative Hepatocellular Carcinoma
Abstract
Background: Currently, there is still a lack of effective biomarkers for the recurrence monitoring and survival prognosis assessment of hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP)-negative (≤20 ng/mL) after radical resection.
Methods: The clinicopathological data of 606 patients (303 in the AFP-negative group and 303 in the AFP-positive group) who underwent radical resection of HCC were analyzed retrospectively.
Results: The gamma-glutamyl transpeptidase to lymphocyte count ratio (GLR) of patients in the AFP-negative group was lower than that in the AFP-positive group (p <0.001). The GLR level of the early-recurrence group was higher than that of the non-early-recurrence group (p =0.003). GLR had fair accuracy in predicting the early-recurrence of HCC patients [c-index=0.654 (95% CI=0.606-0.702); AUC=0.681 (95% CI=0.625-0.733)]. Univariate analysis showed that patients with tumor size <5 cm, no microvascular invasion, single tumor, no metastasis, BCLC stage 0-A, no recurrence, and GLR ≤45.0 had longer disease-free survival (DFS) and overall survival (OS) among AFP-negative HCC patients. In addition, multivariate Cox proportional hazards regression analysis showed that tumor size <5 cm (p =0.003), no recurrence (p <0.001), and GLR <45.0 (p <0.001) were independent predictors of longer OS.
Conclusion: GLR may be a potential indicator for early recurrence monitoring and prognosis evaluation in HCC patients with AFP-negative after radical resection.
Keywords: AFP-negative; GLR; early-recurrence; hepatocellular carcinoma; prognosis.
© 2021 Li et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures



Similar articles
-
A new model based on gamma-glutamyl transpeptidase to lymphocyte ratio and systemic immune-inflammation index can effectively predict the recurrence of hepatocellular carcinoma after liver transplantation.Front Oncol. 2023 Apr 20;13:1178123. doi: 10.3389/fonc.2023.1178123. eCollection 2023. Front Oncol. 2023. PMID: 37152021 Free PMC article.
-
Prognostic Value of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in Patients With Single Tumor Size ≤ 5 cm Hepatocellular Carcinoma After Radical Resection.Front Oncol. 2019 May 21;9:347. doi: 10.3389/fonc.2019.00347. eCollection 2019. Front Oncol. 2019. PMID: 31165038 Free PMC article.
-
Predictive value of gamma-glutamyl transpeptidase to lymphocyte count ratio in hepatocellular carcinoma patients with microvascular invasion.BMC Cancer. 2020 Feb 18;20(1):132. doi: 10.1186/s12885-020-6628-7. BMC Cancer. 2020. PMID: 32070301 Free PMC article.
-
The Combination of Age, International Standardized Ratio, Albumin and γ-Glutamyl Transpeptidase (AIAG), Tumor Size and Alpha Fetoprotein (AFP) Stage as the Prognostic Model for Hepatitis B-Related Hepatocellular Carcinoma.Int J Gen Med. 2021 Aug 10;14:4291-4301. doi: 10.2147/IJGM.S323293. eCollection 2021. Int J Gen Med. 2021. PMID: 34408472 Free PMC article.
-
Novel Biomarkers in Hepatocellular Carcinoma from Embryogenic Antigens to cfDNA.Biomedicines. 2025 Apr 23;13(5):1020. doi: 10.3390/biomedicines13051020. Biomedicines. 2025. PMID: 40426850 Free PMC article. Review.
Cited by
-
Novel Nomograms Based on Gamma-Glutamyl Transpeptidase-to-Lymphocyte Ratio Predict Prognosis of Hepatocellular Carcinoma Patients After Hepatectomy.J Hepatocell Carcinoma. 2023 Feb 9;10:217-230. doi: 10.2147/JHC.S391755. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36798739 Free PMC article.
-
Nomogram Based on Platelet-Albumin-Bilirubin for Predicting Tumor Recurrence After Surgery in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients.J Hepatocell Carcinoma. 2023 Jan 13;10:43-55. doi: 10.2147/JHC.S396433. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36660412 Free PMC article.
-
A new model based on gamma-glutamyl transpeptidase to lymphocyte ratio and systemic immune-inflammation index can effectively predict the recurrence of hepatocellular carcinoma after liver transplantation.Front Oncol. 2023 Apr 20;13:1178123. doi: 10.3389/fonc.2023.1178123. eCollection 2023. Front Oncol. 2023. PMID: 37152021 Free PMC article.
-
Early identification of hepatocellular carcinoma patients at high-risk of recurrence using the ADV score: a multicenter retrospective study.World J Surg Oncol. 2024 Sep 7;22(1):240. doi: 10.1186/s12957-024-03523-1. World J Surg Oncol. 2024. PMID: 39244533 Free PMC article.
-
Development and validation of a nomogram to predict the recurrence of hepatocellular carcinoma patients with dynamic changes in AFP undergoing locoregional treatments.Front Oncol. 2023 Aug 28;13:1206345. doi: 10.3389/fonc.2023.1206345. eCollection 2023. Front Oncol. 2023. PMID: 37700838 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources